Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Jan Cerny"'
Autor:
Agrima Mian, Wei Wei, Rajshekhar Chakraborty, Jean C. Yi, Jaime M. Preussler, Brian T. Hill, Jan Cerny, Abhinav Deol, Theresa E. Hahn, Shahrukh K. Hashmi, Samantha Jaglowski, Heather S.L. Jim, Nandita Khera, Alison W. Loren, Joseph P. McGuirk, Bipin N. Savani, Patrick Stiff, Joseph P. Uberti, Victoria Whalen, John R. Wingard, Jana Reynolds, Shernan G Holtan, William A. Wood, K. Scott Baker, Karen L. Syrjala, Betty K. Hamilton, Navneet S. Majhail
Publikováno v:
Blood. 140:8019-8021
Autor:
Shyam A Patel, Jan Cerny, William K Gerber, Andrew Gillis-Smith, Muthalagu Ramanathan, Sakiko Suzuki, Lloyd Hutchinson, Anne Higgins, Patricia Minehart Miron, Ryan Horgan, Andrea Milano, Christie Perron, Rachel Pransky, Lindsey Shanahan, Karl Simin, Alyssa Tonelli, Jonathan M Gerber
Publikováno v:
Blood. 140:6276-6278
Autor:
Shyam A Patel, William K Gerber, Lloyd Hutchinson, Shrinkhala Khanna, Jan Cerny, Muthalagu Ramanathan, Andrew Gillis-Smith, Sakiko Suzuki, Gregory A. Abel, Salwa Khedr, William Selove, Bruce Woda, Rena Zheng, Patricia Minehart Miron, Anne Higgins, Jonathan M Gerber
Publikováno v:
Blood. 140:5756-5758
Autor:
Shyam A Patel, William K Gerber, Lloyd Hutchinson, Jan Cerny, Muthalagu Ramanathan, Andrew Gillis-Smith, Sakiko Suzuki, Salwa Khedr, Bruce Woda, William Selove, Jonathan M Gerber
Publikováno v:
Blood. 140:9150-9151
Autor:
Neeraj Saini, Vanessa Fiorini Furtado, Jan Cerny, Rajneesh Nath, Imran Puthawala, Muthalagu Ramanathan, Angela Desmond
Publikováno v:
Blood. 132:1396-1396
Intro: Assessment of induction mortality risk in acute myeloid leukemia (AML) patients is challenging. Hematopoietic cell transplant comorbidity index (HCT-CI) score was designed for risk assessment of patients undergoing an allogeneic transplant. Ho
Autor:
Lindsey Shanahan, Glen D. Raffel, Vanessa Fiorini Furtado, Rajneesh Nath, Patricia M. Miron, Angela Desmond, Neeraj Saini, Imran Puthawala, Muthalagu Ramanathan, Zheng Zhou, Jan Cerny, Bruce A. Woda, Jayde Bednarik
Publikováno v:
Blood. 132:1430-1430
Introduction In acute myeloid leukemia (AML), dose intensification of "7+3" has not produced improved outcomes. At our center, we evaluated an intensive "5+1" regimen of high dose mitoxantrone (HDM) with high dose cytarabine (HiDAC) in all newly diag
Autor:
Muhammad Wagas Khan, Gulrayz Ahmed, Mrinal M. Patnaik, Gerhard C. Hildebrandt, Moussab Damlaj, Zartash Guth, Hassan B. Alkhateeb, Rajneesh Nath, Wael Saber, Marcos de Lima, Jan Cerny, Brenda M. Sandmaier, Mark R. Litzow, Khalid Bo-Subait, Daniel J. Weisdorf, Zheng Zhou, Hai-Lin Wang
Publikováno v:
Blood. 132:3456-3456
Background: There is limited data comparing the outcomes of the two most common (FM or FB) RIC regimens in AML. Previous smaller retrospective studies suggest increased non-relapse mortality (NRM) but decreased relapse with FM based RIC with a variab
Autor:
Mark R. Litzow, Jan Cerny, Martin S. Tallman, Stephen A. Strickland, Hillard M. Lazarus, Witold B. Rybka, Xin Victoria Wang
Publikováno v:
Blood. 128:4053-4053
Introduction: High-dose cytarabine consolidation chemotherapy for acute myeloid leukemia (AML) induces profound transient myelosuppression. Thrombocytopenia is a limiting factor in chemotherapy administration for maintaining dose intensity and schedu
Autor:
Rajneesh Nath, Jan Cerny, Glen D. Raffel, Zheng Zhou, Jayde Bednarik, Neng Yu, Muthalagu Ramanathan
Publikováno v:
Blood. 128:5875-5875
Background: Allo-SCT is a curative option for patients with AML and MDS. It is unclear whether there is an upper age limit for Allo-SCT. CIBMTR showed similar outcomes for patients older than 65 years after Allo-SCT (McClune et al J Clin Oncol 28:187
Autor:
Michael A. Brehm, Alan G. Rosmarin, Hong Zhang, Nicole C. Walsh, Dale L. Greiner, Andrew M. Evens, Jack L. Leonard, Jan Cerny, Zheng Zhou, Leonard D. Shultz, Rachel M. Gerstein, Bruce A. Woda, Rita Bortell, Giles F. Whalen
Publikováno v:
Blood. 126:5408-5408
Introduction: In the United States, over 90% of non-Hodgkin's lymphomas (NHL) are derived from mature B lymphocytes. More than 500,000 individuals in the U.S. are living with non-Hodgkin's lymphoma, yet despite an improving 5-year survival rate estim